H

Huakang Biomedical Holdings Co Ltd
HKEX:8622

Watchlist Manager
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Watchlist
Price: 0.184 HKD -0.54%
Market Cap: 92.1m HKD
Have any thoughts about
Huakang Biomedical Holdings Co Ltd?
Write Note

Huakang Biomedical Holdings Co Ltd
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Huakang Biomedical Holdings Co Ltd
Cost of Revenue Peer Comparison

Comparables:
K
876
K
1134
1120
O
6929

Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
H
Huakang Biomedical Holdings Co Ltd
HKEX:8622
Cost of Revenue
-ÂĄ8.7m
CAGR 3-Years
-6%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
K
Kaisa Health Group Holdings Ltd
HKEX:876
Cost of Revenue
-HK$101.4m
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
9%
K
Kelfred Holdings Ltd
HKEX:1134
Cost of Revenue
-HK$336.3m
CAGR 3-Years
-5%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Arts Optical International Holdings Ltd
HKEX:1120
Cost of Revenue
-HK$864.4m
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
4%
O
OrbusNeich Medical Group Holdings Ltd
HKEX:6929
Cost of Revenue
-$47.4m
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A

See Also

What is Huakang Biomedical Holdings Co Ltd's Cost of Revenue?
Cost of Revenue
-8.7m CNY

Based on the financial report for Dec 31, 2023, Huakang Biomedical Holdings Co Ltd's Cost of Revenue amounts to -8.7m CNY.

What is Huakang Biomedical Holdings Co Ltd's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-4%

Over the last year, the Cost of Revenue growth was -4%. The average annual Cost of Revenue growth rates for Huakang Biomedical Holdings Co Ltd have been -6% over the past three years , -4% over the past five years .

Back to Top